[{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Sonnet BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Holdings Announces Merger Closing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"New Life Therapeutics","pharmaFlowCategory":"D","amount":"$40.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"New Life Therapeutics","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"$1.0 million","newsHeadline":"Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan Capital Markets","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Early Safety Data from the Company\u2019s Phase 1b\/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study\u2019s Initial Pre-Specified Objective","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Sonnet BioTherapeutics
SON-080 is a low dose recombinant human interleukin-6 (rhIL-6), which is currently being evaluated for the treatment of chemotherapy-induced peripheral neuropathy.
Sonnet anticipates using the net proceeds from the offering for research and development, including SON-1010 (IL12-FHAB), a proprietary version of native human IL-12, configured using Sonnet's fully human albumin binding (FHAB®) platform.
SON-1010 (IL12-FHAB), a proprietary version of IL-12, under development of solid tumors. In POC studies indicated that mIL12-FHAB had significantly higher tumor accumulation, 2.5-4.7 times higher on average at the longer time points, and increased retention when compared to mIL-12.
SON-1010 is a proprietary version of recombinant human Interleukin 12, configured using the FHAB technology that targets tumor and lymphatictissue, which is being investigated with a fixed dose of atezolizumab for the treatment of platinum-resistant ovarian cancer.
The Company intends to use the net proceeds for research and development, including its lead product SON-1010, a proprietary version of native human IL-12, under development for the treatment of solid tumors.
SON-1010 is a proprietary version of recombinant human Interleukin 12 (IL-12), configured using the FHAB technology that targets tumor and lymphatictissue, which is investigated for the treatment of patients with advanced solid tumors.
SON-1010 is a proprietary version of recombinant human Interleukin 12 (IL-12), configured using the FHAB technology that targets tumor and lymphatictissue.
Net proceeds will be used by Lirum primarily to advance its clinical and preclinical studies and development of lead candidate SON-080, for working capital, and to potentially expand its product candidate pipeline.
SON-1010 is a immunotherapeutic recombinant drug that links unmodified singlechain human IL-12 with the albumin-binding domain. It delivers IL-12 to local tumor tissue and stimulates IFNg, which activates immune cells and increases the production of PD-L1 on tumor cells.
SON-1010 (IL12-FHAB) is a candidate immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
